Besides, a decline in yearly mortality has also been observed and might be ascribed to the higher survival of patients due to the new immunotherapy treatment with ipilimumab, the first immune checkpoint inhibitor approved for cancer therapy, and the targeted therapy with vemurafenib, a BRAF inhibitor (BRAFi) for the treatment of advanced melanoma approved by the Food and Drug Administration (FDA) in 2011. Here, BRAF is linked to melanoma.